Literature DB >> 6334741

D-Penicillamine induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3.

P Emery, G S Panayi, G Huston, K I Welsh, S C Mitchell, R R Shah, J R Idle, R L Smith, R H Waring.   

Abstract

Sulphoxidation of carbocysteine, a drug structurally similar to D-penicillamine, displays a skewed distribution within a population. In 66 patients with rheumatoid arthritis (RA) a significant association between impaired sulphoxidation and toxicity (p less than 0.001) was found; HLA-DR3, although associated with toxicity (p less than 0.05), appeared to be an independent risk factor of most importance in the group with extensive sulphoxidation. The relative risk of toxicity in a patient possessing either DR3 or impaired sulphoxidation was 25. The prevalence of poor sulphoxidizers within this group of RA patients was increased compared to that in a previous population study and requires further investigation. Our findings explain a number of the toxic phenomena associated with D-penicillamine administration in RA.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6334741

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  20 in total

Review 1.  Idiosyncratic drug reactions: a mechanistic evaluation of risk factors.

Authors:  B K Park; M Pirmohamed; N R Kitteringham
Journal:  Br J Clin Pharmacol       Date:  1992-11       Impact factor: 4.335

Review 2.  Immunotoxicology: suppressive and stimulatory effects of drugs and environmental chemicals on the immune system. A discussion.

Authors:  E Gleichmann; I Kimber; I F Purchase
Journal:  Arch Toxicol       Date:  1989       Impact factor: 5.153

Review 3.  Drug-related lupus. Incidence, mechanisms and clinical implications.

Authors:  L E Adams; E V Hess
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

4.  Increased prevalence of poor sulphoxidation in patients with rheumatoid arthritis: effect of changes in the acute phase response and second line drug treatment.

Authors:  P Emery; H Bradley; A Gough; V Arthur; R Jubb; R Waring
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

5.  Does sulphoxidation state predict gold toxicity in rheumatoid arthritis?

Authors:  R Madhok; H A Capell; R Waring
Journal:  Br Med J (Clin Res Ed)       Date:  1987-02-21

Review 6.  Immunotoxic side-effects of drug therapy.

Authors:  J A Mitchell; E M Gillam; L A Stanley; E Sim
Journal:  Drug Saf       Date:  1990 May-Jun       Impact factor: 5.606

7.  Inhibition of the covalent binding reaction of complement component C4 by penicillamine, an anti-rheumatic agent.

Authors:  E Sim; A W Dodds; A Goldin
Journal:  Biochem J       Date:  1989-04-15       Impact factor: 3.857

8.  Evaluation of proposed sulphoxidation pathways of carbocysteine in man by HPLC quantification.

Authors:  J Brockmöller; B Staffeldt; I Roots
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  A western blot approach to detection of human plasma protein conjugates derived from D-penicillamine.

Authors:  C A Laycock; M J Phelan; R C Bucknall; J W Coleman
Journal:  Ann Rheum Dis       Date:  1994-04       Impact factor: 19.103

10.  A T-cell response to the anti-arthritic drug penicillamine in the mouse: requirements for generation of the drug-derived antigen.

Authors:  C A O'Donnell; J W Coleman
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.